PCSA · Insider Trading
Processa Pharmaceuticals, Inc. Common
Every open-market purchase and sale reported by PCSA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | George K Ng | Chief Executive Officer | M | +1,600 | — |
| 2026-07-30 | Sheila Gujrathi | Director | A | +83,123 deriv. | — |
| 2026-07-28 | Geraldine Pannu | Director | A | — | — |
| 2026-07-28 | Patrick Lin | Chief Business - Strategy Off | A | — | — |
| 2026-07-28 | James R Neal | Director | A | — | — |
| 2026-07-28 | Russell Skibsted | Chief Financial Officer | A | — | — |
| 2026-07-28 | George K Ng | Chief Executive Officer | A | — | — |
| 2026-07-28 | Justin W Yorke | Director | A | — | — |
| 2026-07-28 | Khoso Baluch | Director | A | — | — |
| 2026-07-28 | Wendy Guy | Chief Administrative Officer | A | — | — |
| 2026-07-01 | Russell Skibsted | Chief Financial Officer | Buy | +3,277 | +$6.32K |
| 2026-07-01 | George K Ng | Chief Executive Officer | Buy | +3,057 | +$5.90K |
| 2026-07-01 | Patrick Lin | Chief Business - Strategy Off | Buy | +2,106 | +$4.06K |
| 2026-07-01 | David Young | Pres. Research & Development | Buy | +2,531 | +$4.88K |
| 2026-07-01 | Wendy Guy | Chief Administrative Officer | Buy | +2,436 | +$4.70K |
| 2026-06-16 | Patrick Lin | Chief Business - Strategy Off | Buy | +1,831 | +$4.06K |
| 2026-06-16 | Wendy Guy | Chief Administrative Officer | Buy | +2,118 | +$4.70K |
| 2026-06-16 | George K Ng | Chief Executive Officer | Buy | +2,465 | +$5.47K |
| 2026-06-16 | Russell Skibsted | Chief Financial Officer | Buy | +2,654 | +$5.89K |
| 2026-06-16 | David Young | Pres. Research & Development | Buy | +2,067 | +$4.59K |
| 2026-06-01 | Patrick Lin | Chief Business - Strategy Off | Buy | +1,582 | +$4.07K |
| 2026-06-01 | Russell Skibsted | Chief Financial Officer | Buy | +2,292 | +$5.89K |
| 2026-06-01 | David Young | Pres. Research & Development | Buy | +1,786 | +$4.59K |
| 2026-06-01 | George K Ng | Chief Executive Officer | Buy | +2,129 | +$5.47K |
| 2026-06-01 | Wendy Guy | Chief Administrative Officer | Buy | +1,829 | +$4.70K |
| 2026-05-19 | Russell Skibsted | Chief Financial Officer | Buy | +1,984 | +$5.89K |
| 2026-05-19 | Sian Bigora | Chief Development Officer | Buy | +1,971 | +$5.34K |
| 2026-05-19 | Patrick Lin | Chief Business - Strategy Off | Buy | +1,369 | +$4.07K |
| 2026-05-19 | George K Ng | Chief Executive Officer | Buy | +1,843 | +$5.47K |
| 2026-05-19 | George K Ng | Chief Executive Officer | Buy | +1,843 | +$5.47K |
| 2026-05-19 | Wendy Guy | Chief Administrative Officer | Buy | +1,583 | +$4.70K |
| 2026-05-19 | David Young | Pres. Research & Development | Buy | +1,545 | +$4.59K |
| 2026-05-01 | Sian Bigora | Chief Development Officer | Buy | +1,986 | +$5.34K |
| 2026-05-01 | Russell Skibsted | Chief Financial Officer | Buy | +2,190 | +$5.89K |
| 2026-05-01 | Wendy Guy | Chief Administrative Officer | Buy | +1,748 | +$4.70K |
| 2026-05-01 | David Young | Pres. Research & Development | Buy | +1,706 | +$4.59K |
| 2026-05-01 | Patrick Lin | Chief Business - Strategy Off | Buy | +1,511 | +$4.06K |
| 2026-05-01 | George K Ng | Chief Executive Officer | Buy | +2,034 | +$5.47K |
| 2026-04-17 | Russell Skibsted | Chief Financial Officer | Buy | +1,984 | +$5.89K |
| 2026-04-17 | Sian Bigora | Chief Development Officer | Buy | +1,799 | +$5.34K |
| 2026-04-17 | Wendy Guy | Chief Administrative Officer | Buy | +1,583 | +$4.70K |
| 2026-04-17 | George K Ng | Chief Executive Officer | Buy | +1,843 | +$5.47K |
| 2026-04-17 | David Young | Pres. Research & Development | Buy | +1,545 | +$4.59K |
| 2026-04-17 | Patrick Lin | Chief Business - Strategy Off | Buy | +1,369 | +$4.07K |
| 2026-04-02 | James R Neal | Director | Buy | +789 | +$2.00K |
| 2026-04-01 | Geraldine Pannu | Director | Buy | +2,072 | +$5.25K |
| 2026-04-01 | Russell Skibsted | Chief Financial Officer | Buy | +2,324 | +$5.89K |
| 2026-04-01 | Sian Bigora | Chief Development Officer | Buy | +2,107 | +$5.34K |
| 2026-04-01 | George K Ng | Chief Executive Officer | Buy | +2,136 | +$5.41K |
| 2026-04-01 | Wendy Guy | Chief Administrative Officer | Buy | +1,854 | +$4.70K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| David Young | Pres. Research & Development | 22,971 | $41.23K |
| George K Ng | Chief Executive Officer | 17,892 | $32.12K |
| Russell Skibsted | Chief Financial Officer | 16,689 | $29.96K |
| Patrick Lin | Chief Business - Strategy Off | 14,853 | $26.66K |
| Wendy Guy | Chief Administrative Officer | 14,727 | $26.43K |
| Sian Bigora | Chief Development Officer | 7,748 | $13.91K |
| Khoso Baluch | Director | 2,528 | $4.54K |
| Geraldine Pannu | Director | 2,391 | $4.29K |
| James R Neal | Director | 1,021 | $1.83K |
| Justin W Yorke | Director | 849 | $1.52K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PCSA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.